References

Czech and Slovak Ophthalmology

Original article

Combination of intravitreal corticosteroid with anti-VEGF in macular edema secondary to retinal vein occlusion

Valášková

Jela

https://orcid.org/0009-0002-4740-2587

Popov

Ivajlo

https://orcid.org/0000-0001-6368-0347

Krásnik

Vladimír

30 1 2018

5+6

Purpose: functioal and anatomical results afer combinationof intravitreal dexamethasone implant with anti-VGF bevacizumab in macular edema secondary to retinal ein occlusion. Methods: Retrospectie analysis of 50 patints, average age 72 years, 15 men and 35 women. Inclusion criteria for treatment were retinalvein occlusion, best corrected visual acuity (BCVA) more than 20/200 and macular edema more than 250 μm. Algorithm of treatment was dexamethason, anti-VGF (bevacizumab), dexamethason. Applicationof anti-VGF bevacizumab was in interval between two applicationsof dexamethasone, for the fist timein every patiet. If there were nonperfusion areas on fluoesceine angiography (FA), or ischemia on slit lamp, repeatedly. Patiets observed for 12 months at least. This cohort included patiets with branch retinalvein occlusion together with central retinalvein oc-clusion. This is an evaluationof nonperfusion areas based on FA, BCVA, macular edema on optial coherence tomography (OCT) and number of reapplicationof anti-VGF bevacizumab. Observed adverse efects are elevationof intraocular pressure and number of patiets who underwent cataract surgery. Results: The gain of 8 letters in 1st month after 1st application of dexamethasone, central retinal thickness (CRT) reduced from 512 μm to 318 μm in average. 33 patients get 1, 3 patients get 2 and 14 patients 3 injections of bevacizumab. On the day of 2nd application of dexamethasone, in 7th month in average, the CRT increased on 465 μm, and 1th month after, the gain from the baseline was 10 letters and CRT reduced on 380 μm. All the pa-tients were phackic at the baseline, 18 (36 %) patients underwent cataract surgery with intraocular lens implantation. Transient elevation of intraocular pressure in 15 (30 %) eyes, treated by local therapy. Conclusion: Combination of intravitreal dexamethasone implant with anti-VEGF bevaci-zumab is functionally and anatomically effective.

retinal ein occlusion macular edema dexamethasone bevacizumab

References

Drechsler, F., Köferl, P., Hollborn, M. et al.: Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion. Ophthalmic Res, 47(3); 2012: 157–162. 4. Glacet-Bernard, A., Coscas, G., Chabanel, A. et al.: Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology, 1. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous haemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol, 104(1); 1986: 34–41. 2. Cugatti, S., Wang, J.J., Rochtchina, E. et al.: Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol, 103; 1996: 551–60.

Haller, J.A., Bandello, F., Belfort, R. Jr. et al.: OZURDEX GENEVA Study Group, Randomized, sham-control trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology, 117(6); 2010: 1134-1146. 6. Haller, J.A., Bandello, F., Belfort, R. Jr. et al.: Ozurdex GENEVA Study Group: Dexamethasone intravitreal implant in patients with macular edema GENEVA study. During the GENEVA study, the occurrence of cataract was recorded in 29.8% after the 2nd application of Ozurdex®, in our cohort 36% of patients underwent cataract surgery during the course of treatment, which is connected not only with the application of Ozurdex® but also with the average age of the cohort, i.e. 72 years, as well as with the presence of opacities of the lens at the beginning of treatment. Increased intraocular pressure was recorded in 25.5% of patients during the GENEVA study. On our cohort we recorded 30% of patients with increased intraocular pressure. In the st

Hariprasad, S.M.(Ed): Management of Retinal Vein Occlusion. Current Concepts, Slack, 2014, 5 p.

Hayreh, S.S., Zimmerman, M.B., Beri, M. et al.: Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlu- sion. Ophthalmology, 111; 2004: 133–41.

Hayreh, S.S., Zimmermann, M.B., Podhajsky, P.: Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol, 117(4); 1994: 429–41. 10. Ho, M., Liu, D.T., Lam, D.S. et al.: Retinal vein occlusions, from basics to the latest treatment. Retina, 36(3); 2016: 432–48. 11. Ip, M.S., Scott, I.U., VanVeldhuisen, P.C. et al.: The SCORE Study Research Group. A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. Arch Ophthalmol, 127(9); 2009: 1101–1114.

Jalkh, A.E., Avila, P.M., Zakka, K.A. et al.: Chronic macular oedema in retinal branch occlusion: role of laser photo- coagulation. Ann Ophthalmol, 16(6); 1984: 532–3. 13. Klein, R., Klein, B.E., Moss, S.E. et al.: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophtalmol Soc, 98; 2000: 133–41. 14. Mayer, W.J., Wolf, A., Kernt, M. et al.: Twelve-month experience with Ozurdex for the treatment of macular edema as- sociated with retinal vein occlusion. Eye (Lond), 27(7); 2013: 816–22.

Mitchell, P., Smith, W., Chang, A.: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol, 114(10);1996: 1243–7. 16. Noma, H., Funatsu, H., Harino, S. et al.: Vitreous inflammatory factors in macu- lar edema with central retinal vein oc- clusion. Jpn J Ophthalmol, 55(3); 2011: 248–55. 17. Noma, H., Funatsu, H., Mimura, T. et al.: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology, 116(1); 2009 Jan: 87–93.

Pommier, S., Meyer, F., Guigou, S. et al.: Long-Term Real-Life Efficacy and Safety of Repeated Ozurdex® Injections and Factors Associated with Macular Edema Resolution after Retinal Vein Occlusion: The REMIDO 2 Study. Ophthalmologica, 236(4); 2016: 186–192. 19. Quinlan, P.M., Elman, M.J., Bhatt, A.K. et al.: Natural course of central retinal vein occlusion. Am J Ophthalmol, 110(2); 1990: 118–23. 20. Rehak, M., Hollborn, M., Iandiev, I. et al.: Retinal gene expression and Müller cell responses after branch retinal vein occlusion in the rat. Invest Ophthalmol Vis Sci, 50(5); 2009: 2359–67.

Risk factors for branch retinal vein occlusion. The Eye Disease Case – Control Study Group. Am J Ophthalmol, 116(3); 1993: 286–296. 22. Risk factors for central retinal vein occlusion. The Eye Disease Case – Control Study Group. Arch Ophthalmol, 114(5); 1996: 545–554. 23. Rogers, S., McIntosh, R.L., Cheung, N. et al.: International Eye Disease Consortium: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology, 117(2); 2010: 313–9. 24. Řehák, J., Řehák, M.: Venózní okluze sítnice, Grada Publishing, 2011, 58 s.

Řehák, J., Řehák, M.: Venózní okluze sítnice, Grada Publishing, 2011, 59 s.

Scott, I.U., Ip, M.S., VanVeldhuisen, P.C. et al.: SCORE Study Research G r oup: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol, 127; 2009: 1115–28. 27. Shahid, H., Hossain, P., Amoaku, W.M.: The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol, 90(5); 2006: 627–39. 28. Shimura, M., Nakazawa, T., Yasuda, K. et al.: Visual prognosis and vitre- ous cytokine levels after arteriovenous sheathotomy in branch retinal vein oc- clusion associated with macular oede- ma. Acta ophthalmologica, 86(4); 2008: 377–84.

Singer, M.A., Bell, D.J., Woods, P. et al.: Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with reti- nal vein occlusion. Retina, 32(7); 2012: 1289–94. 30. Suzuki, Y., Nakazawa, M., Suzuki, K. et al.: Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein oc- clusion, 55(3); 2011: 256–63. 31. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular ede- ma in central retinal vein occlusion. Ophtalmology, 102; 1995: 1425–33. 32. Yoshimura, T., Sonoda, K.H., Sugahara, M. et al.: Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One, 4(12); 2009: e8158. 33. Zhao, J., Sastry, S.M., Sperduto, R.D. et al.: Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Ophthalmology, 100(3); 1993: 423–8.